IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

BACKGROUND: The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients. RESULTS: A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 compl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cerebellum Ataxias
Egile Nagusiak: Sanz-Gallego, Irene, Rodriguez-de-Rivera, Francisco J, Pulido, Irene, Torres-Aleman, Ignacio, Arpa, Javier
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552149/
https://ncbi.nlm.nih.gov/pubmed/26331037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40673-014-0013-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak